

ATC codes: **L02BA01**

Indication	Malignant neoplasms of breast <span>ICD11 code: <b>2D2Z</b></span>
INN	Tamoxifen
Medicine type	Chemical agent
List type	Complementary
Formulations	Oral > Solid: 10 mg (as citrate) ; 20 mg (as citrate)
EML status history	First added in 1984 ( <a href="#">TRS 722</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 

## Tags

Cancer

## Wikipedia

[Tamoxifen](#) 

## DrugBank

[Tamoxifen](#) 

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for tamoxifen on the complementary list of the EML for use in treatment protocols for hormone-receptor positive early stage breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for early stage breast cancer is attached.

[Expert Committee report](#) 

